0000899243-17-024245.txt : 20171016
0000899243-17-024245.hdr.sgml : 20171016
20171016170345
ACCESSION NUMBER: 0000899243-17-024245
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171013
FILED AS OF DATE: 20171016
DATE AS OF CHANGE: 20171016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheung Wilson Wai-Shun
CENTRAL INDEX KEY: 0001291656
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 171139289
MAIL ADDRESS:
STREET 1: SCICLONE PHARMACEUTICALS, INC.
STREET 2: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-13
1
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001291656
Cheung Wilson Wai-Shun
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
0
1
0
0
CFO & Senior VP, Finance
Common Stock
2017-10-13
4
M
0
52000
A
69158
D
Common Stock
2017-10-13
4
A
0
75000
0.00
A
144158
D
Common Stock
2017-10-13
4
D
0
144158
11.18
D
0
D
Non-Qualified Stock Option (right to buy)
5.97
2017-10-13
4
D
0
9375
5.21
D
2023-08-09
Common Stock
9375
0
D
Non-Qualified Stock Option (right to buy)
4.52
2017-10-13
4
D
0
24792
6.66
D
2024-03-14
Common Stock
24792
0
D
Incentive Stock Option (right to buy)
8.83
2017-10-13
4
D
0
39225
2.35
D
2025-03-16
Common Stock
39225
0
D
Restricted Stock Unit
2017-10-13
4
M
0
6000
D
Common Stock
6000
0
D
Non-Qualified Stock Option (right to buy)
8.83
2017-10-13
4
D
0
44775
2.35
D
2025-03-16
Common Stock
44775
0
D
Restricted Stock Unit
2017-10-13
4
M
0
25000
D
Common Stock
25000
0
D
Incentive Stock Option (right to buy)
9.12
2017-10-13
4
D
0
11131
2.06
D
2026-03-15
Common Stock
11131
0
D
Non-Qualified Stock Option (right to buy)
9.12
2017-10-13
4
D
0
72869
2.06
D
2026-03-15
Common Stock
72869
0
D
Restricted Stock Unit
2017-10-13
4
M
0
9000
D
Common Stock
9000
0
D
Restricted Stock Unit
2017-10-13
4
M
0
12000
D
Common Stock
12000
0
D
Incentive Stock Option (right to buy)
9.65
2017-10-13
4
D
0
10651
1.53
D
2027-03-08
Common Stock
10651
0
D
Non-Qualified Stock Option (right to buy)
9.65
2017-10-13
4
D
0
73349
1.53
D
2027-03-08
Common Stock
73349
0
D
Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
Shares of SCLN common stock received in settlement of performance rights not constituting derivative securities.
Granted under Issuer's 2005 Equity Incentive Plan.
Under its terms the option became exercisable in installments with 25% vesting on August 9, 2014 and 2.0833% vesting each month thereafter until it became vested in full on August 9, 2017.
The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
Under its terms the option became exercisable in installments with 25% vesting on March 14, 2014 and 2.0833% vesting each month thereafter until it became vested in full on March 15, 2017.
Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.
Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
Under its terms the option became exercisable in installments with 25% vesting on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
Granted under Issuer's 2015 Equity Incentive Plan.
/s/ Wilson W. Cheung
2017-10-16